PROM1 and neoplasm: We found that the chemotherapeutic drug (0.5 nM) combined with 4Mu significantly reduced colony formation in CD133+ cells (p < 0.01; Fig. 4C) and inhibited tumor-formation capacity in CD133+ cells (p < 0.05; Fig. 4C).